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ABSTRACT
Objectives: Quality-controlled mammography screening
programs (MSP) have led to a reduction in breast cancer
mortality. The purpose of this economic analysis was to
assess the cost-effectiveness of MSP compared with an
established opportunistic screening strategy (OS) in Switzer-
land, to identify the major factors inﬂuencing the economic
outcome.
Methods: Using cancer registries and clinical data, a
Markov-based decision model was designed to compare MSP
with OS in the Swiss female population, considering the main
screening-speciﬁc performance parameters.
Results: The discounted incremental life expectancy
amounted to 0.022 life-years gained in favor of MSP when
screening started at age 40 years and decreased to
0.008 years at the age of 70 years (number needed to screen
to avoid one death over 10 years ranged from 10,000 to
2439 women depending on the baseline age). The total dis-
counted life-time cost for screening, treatment at the baseline
age of 40 years amounted in MSP to $4366 (OS: $2802) and
decreased with the baseline age of 70 years to $2412 (OS:
$1446). The discounted incremental cost-effectiveness ratio
comparing MSP versus OS ranged from $73,018 (age
40 years) to $118,193 (age 70 years) per life-year gained.
Testing all model variables conﬁrmed that both incidence
and mortality of breast cancer play the most important role
in the health economic outcome, whereas cost and perform-
ances (sensitivity, speciﬁcity) of screening had a minor impact
on the efﬁciency.
Conclusion: This analysis, performed under conservative
assumptions, supports that MSP in Switzerland enables a rel-
evant reduction of breast cancer mortality, at moderate addi-
tional cost, compared with OS.
Keywords: cost-effectiveness, health economics, quality-
controlled mammography Screening, Switzenland.
Introduction
The main objective of screening is to reduce the burden
of a disease by detecting it in an early stage where an
effective treatment enhances the chance of survival. A
screening test separates apparently healthy, asympto-
matic individuals into those with a high versus a low
probability of the disease. The World Health Organi-
zation (WHO) pioneered the development of criteria
for mass screening [1], and the WHO guidelines have
been widely used for implementing organized screen-
ing programs. According to these guidelines, a screen-
ing test should have a high sensitivity, detecting as
many cases as possible with the disease, and a high
speciﬁcity, preventing further diagnostic tests and
unwarranted treatment in disease-free individuals.
Additionally, the disease should preferably be highly
prevalent in the population because, for a given sensi-
tivity, the chance that a positive screening test will give
a correct result (positive predictive value) increases
with the prevalence of the disease.
Breast cancer is the most frequent cancer among
women in both developing and developed countries,
with 1.1 million new cases being diagnosed each year
[2]. Overall, the incidence increases with age modiﬁed
by environmental factors [3], genetic predisposition
[4], lifestyle [5,6], and use of exogenous hormones
[3,7–9]. Despite being curable when detected at an
early stage, breast cancer is responsible for the deaths
of about 411,000 women worldwide every year [2].
Mammography screening trials have been shown to
signiﬁcantly reduce breast cancer mortality by 21% to
26% in women more than 50 years of age [10,11]. The
mechanism by which mammography screening reduces
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breast cancer mortality is directly related to the
increased chance of detecting a malignant growth at an
earlier, curable stage [12].
Based on clinical practice with an established
opportunistic screening strategy (OS), the achievable
reduction of mortality by a mammography screening
program (MSP) in a setting with OS may range from
5% to 20% [13,14].
The impact of MSP on breast cancer mortality is
strongest for women more than 50 years old. The evi-
dence is weaker for younger women because 1) the
incidence of breast cancer is substantially lower among
women in their 40s, although their cancer is more
often diagnosed as aggressive; 2) the mammography
test is less performing in younger women with denser
breast tissue; and 3) the delay in breast cancer mortal-
ity is difﬁcult to allocate to the beginning of screening
at the age of 40 years rather than at the age of 50 years
[15–17]. Because of the increase in comorbidities, a
decreasing beneﬁt of MSP is assumed at age more than
70 years, even though the sensitivity and speciﬁcity of
MSP improve with increasing age [18,19].
Motivated by positive results obtained in rand-
omized screening trials and meta-analyses evaluating
MSP, breast cancer screening programs have been
introduced in several countries since the mid-1980s
[20,21].
In Switzerland, approximately 5000 breast cancers
are diagnosed each year and about 1350 deaths from
breast cancer are reported [22]. Breast cancer mor-
tality in Switzerland has been decreasing since the
early  1990s,  whereas  the  incidence  of  breast  cancer
is increasing. Reasons underpinning these temporal
changes are multiple, such as better systematic treat-
ment and widespread screening, but also alteration in
risk exposures and lifestyle [23–25].
The feasibility and acceptability within the Swiss
health-care setting of quality assessed MSP have been
demonstrated in a pilot study [21,26]. Since 1999, a
Swiss government edict has been in place to ﬁnance
quality-controlled breast cancer screening programs as
part of the service catalog of statutory health insur-
ances. A Swiss MSP quality standard recommendation
comprises a two-view mammography, with a blinded
double reading performed by two specially trained
radiologists, with a third arbitration reading if neces-
sary, and the screening administration (organization,
invitation, quality assessment, evaluation) [21,27].
Three regional quality-controlled MSP have been
established since 1999 [28].
The efﬁcacy of mammography screening trials was
questioned in a meta-analysis that revealed imbalances
in the characteristics of the screening and control
groups, as well as a discrepancy in the number of ran-
domized women, and concluded that randomized
screening trials yielded no protective effect [29,30].
Most arguments against mass screening and criticisms
based on randomized screening trials have been rebut-
ted and disproved by scientiﬁc reinvestigations con-
ﬁrming that mammography is effective at least in
women older than 50 years [11,31–33]. Despite this,
some debate persists in Switzerland about the pros and
cons of mammography screening, and the medical and
economic beneﬁts of MSP versus OS remain uncertain
[34]. This cost-effectiveness study was performed to
assess the speciﬁc Swiss situation, but because of the
limited and controversial information regarding indi-
rect costs, only direct costs were implemented.
Objective
The purposes of this study were to evaluate the cost-
effectiveness of a quality-controlled MSP compared
with an established OS, and to identify factors in-
ﬂuencing the clinical and economic outcomes with
respect to the beneﬁts, harms, and costs of the tech-
nique from the Swiss third-party payer perspective.
Methods
A comprehensive literature search of English and
German-language publications (studies, meta-analysis,
and reviews) from January 1970 to September 2004
was performed, using the MEDLINE and PubMed
databases and the following terms in different combi-
nations: “breast neoplasm,” “mortality,” “mammog-
raphy,” “mass screening,” “female,” “economic,” and
“cost.”
Model
A Markov model was implemented in the Data Pro
software (TreeAge Inc., Boston, MA) to compare the
health economic effect of a national quality-controlled
MSP with an OS strategy in the Swiss female popula-
tion (Fig. 1). The Markov model is based on a set of
health states linked via transition probabilities, which
were derived from the most relevant sources for the
Swiss context (see Tables 1 and 2). During a simula-
tion run the primary cohort (population at breast can-
cer risk, see Fig. 1) can split into distinct disease states
determined by the transition probabilities. This proc-
ess is repeated for a deﬁned number of cycles, where
the transition from one state to another is calculated
over time in 1-year-cycle lengths. The simulation ends
when the number of predeﬁned cycles or the terminal
state (e.g., death) is reached.
The model starts with a cohort of women being in
a predeﬁned baseline age (40, 50, 60, or 70 years) and
simulates the annual occurrence of malignant (deﬁned
as ductal carcinoma in situ, invasive ductal carcinoma,
or invasive lobular carcinoma) and benign breast
tumors, the detection rate of mammography, the fur-
ther assessment induced by a positive test result, the
recall rate because of false positive test results, and the
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progression of detected and nondetected malignant
breast cancers.
During the simulation the mortality (breast cancer-
related fatality, age-related general mortality), as well
as the screening and treatment costs, was accumulated
over time.
The model compares two scenarios. Scenario 1
assumes that at the beginning of the simulation 70% of
the target population takes part in a biennial quality-
assured MSP whereas the remaining 30% are not
screened (a diagnostic method in a rare disease reaches
the best beneﬁt only if the participation is next to
100%. In a voluntary program this high participation
rate will not be attainable. Therefore, a plausible base-
line participation rate of 70% was speciﬁed. This par-
ticipation rate of 70% corresponds to the European
Guidelines for MSP. This value seems to be the thresh-
old necessary to obtain a MSP-attributable reduction
in breast cancer mortality within a 10-year period).
Nonparticipants will have no beneﬁt from screening.
Because experience from OS in Switzerland is avail-
able for several years [21], scenario 2 assumes a bien-
nial participation rate in OS of 20% at the beginning
of the simulation. In contrast, the residual 80%
receives no screening.
Although OS is not necessarily quality-ensured [35]
and data for its evaluation are limited, this procedure
is likely to impact on breast cancer detection and
achieves some reduction of breast cancer mortality.
The economic impact of different participation rates
was tested within the scope of a sensitivity analysis.
Because  of  the  high  reattendance  rate  and  the
low screening uptake among initial nonparticipants
observed in the Swiss pilot study, the proportion of
women switching between MSP and OS was consid-
ered negligible in this analysis [28].
A quality-of-life analysis was not performed
because the related utilities were not available for
every health state in the model (e.g., false positive
screening results).
Mortality
The overall mortality of the study cohorts was calcu-
lated by combining age- and female-speciﬁc all-cause
mortality rates [36,37] with breast cancer-related fatal-
ity rates of the Swiss female population. These were
derived from mortality associated with ICD-10 (Inter-
national Classiﬁcation of Diseases) code C50 and
published breast cancer survival rates [37–40] The
model-based outcomes were total mortality (%) and
Figure 1 Schema of the Markov model used in the health economic analysis. MSP, mammography screening program; OS, opportunistic screening; P,
probability; RR, relative risk; Sens, sensitivity; Spec, speciﬁcity. 
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remaining life time (years, discounted by 0 and 1.5%
p.a.).
Costs and Perspective
The perspective of the statutory health-care insurance
in Switzerland was adopted. The costs of detecting and
treating breast cancer were separated into three cate-
gories (Table 3). First, there is the cost of mammo-
graphy examination; second, there are the costs of
diagnostic evaluation for mammograms interpreted as
positive (abnormal); and third, there is the cost of
treatment for detected malignant breast cancers.
The cost per mammography varies in MSP between
$104 and $198, of which up to $144 are paid by the
statutory health insurances. About 25% of the total
cost is covered by additional public copayments
[27,41]. Because of this cost sharing, the fee of this
service ranges from $0 to $11 per participant and
screening examination.
The cost of OS has to be paid partly by the individ-
ual herself (copayment). An economic analysis carried
out  in  western  Switzerland  estimated  the  total  cost
of OS (including further investigation) at $240 per
screening [42]. Within the scope of the present
Table 1 Event rates, transition rates, and relative risks used in the model
Model parameter Baseline Range* Source
Annual incidence of breast cancer in 
Swiss female population (P1)
Age (year) Incidence ±10% [22]
40–44 0.0011
45–49 0.0018
50–54 0.0024
55–59 0.0028
60–64 0.0029
65–69 0.0030
70–74 0.0032
75–79 0.0035
80–84 0.0037
85+ 0.0032
Annual fatality rate from breast cancer
(i.e., mortality rate in females with 
breast cancer; P2)
Age (year) Mortality ±10% [22,39,40]
40–44 0.038
45–49 0.041
50–54 0.046
55–59 0.051
60–64 0.058
65–69 0.068
70–74 0.094
75–79 0.143
80–84 0.192
85+ 0.220
Corrected annual all-cause female 
mortality† (P3)
Age (year) Mortality [36,37]
40–44 0.0009
45–49 0.0015
50–54 0.0026
55–59 0.0042
60–64 0.0070
65–69 0.0116
70–74 0.0192
75–79 0.0317
80–84 0.0524
85+ 0.2319
*Applied range in one-way sensitivity analysis and probabilistic sensitivity analysis.
†To avoid double counting of fatal events, all-cause Swiss mortality rates were corrected for breast cancer-related mortality.
Table 2 Mammography screening parameters used in the model and their range of variability applied for the sensitivity analysis
Model parameter Baseline (%) Range(%)* Source
Reduction of breast cancer mortality due to MSP
in a setting with established OS (RR1)
15 13.5–16.5 [13,14]
Proportion of malignant tumor if screening 
positive (PPV) (RR2)
20 18–22 [21]
Sensitivity of MSP (mean value)† (SensMSP) 70 65–86 [21]
Speciﬁcity of MSP (mean value)† (SpecMSP) 96.5 90–98 [21]
Sensitivity of OS (mean value)† (SensOS) 70 63–77 assumption derived from [21]
Speciﬁcity of OS (mean value)† (SpecOS) 90 81–99 assumption derived from [21]
Biennial participation rate in MSP (P4) 70 63–77 [21]
Annual recurrence rate of breast cancer (P5) 5 4.5–5.5 [53]
*Applied range in one-way sensitivity analysis and probabilistic sensitivity analysis.
†The performance values of mammography screening improves with higher age. Because of the lack of information in the Swiss setting the mean values were adapted from Carney
et al. [18].
MSP, mammography screening program; OS, opportunistic screening; P, probability; PPV, positive predictive value; RR, relative risk; Sens, sensitivity; Spec, speciﬁcity.
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economic analysis an estimated amount of $160 is cov-
ered by the statutory health insurances (Personal com-
munication, Dr. de Landtsheer, 2005).
In absence of detailed treatment and follow-up costs
for diagnosed malignant breast cancer in Switzerland,
data from an international cost analysis were used
[43,44]. As a conservative assumption, the follow-up
costs per diagnosed cancer were considered equal in
both screening methods (MSP, OS) and the nonscreen-
ing group. It could, however, be assumed that the lesser
severity of a tumor diagnosed at an earlier stage is
likely to be associated with a lower treatment cost than
that of cases detected at a more advanced stage.
Swiss cost parameters were converted to 2004 val-
ues by an annual inﬂation rate of 1.4% (corresponding
to the average cost increase in the inpatient medical
service in Switzerland over the last 7 years [45]) and an
exchange rate of US$1 = CHF 1.25.
Primary Outcome Measures and Economic Evaluation
The total mortality and the number needed to screen
(NNS) to avoid one death over 10 years as well as life
expectancy were derived from annual breast cancer-
and age-related general mortality. Screening and treat-
ment costs were cumulated over the simulation period.
Life expectancy was discounted at the rates of 0% and
1.5%, and costs at the rates of 0% and 3%, respec-
tively [46].
To compare the cost-effectiveness of MSP versus
OS, the incremental cost-effectiveness ratios (ICER) in
terms of costs per life-year gained (CLYG) were calcu-
lated [47] and deﬁned as
(CMSP − COS)/(LEMSP − LEOS)
where CMSP is the total cost with MSP; COS is the total
cost with OS; LEMSP is the life expectancy with MSP;
and LEOS is the life expectancy with OS.
Sensitivity Analyses/Probabilistic Sensitivity Analysis
Univariate sensitivity analyses were performed to
determine key factors that inﬂuenced incremental
CLYG, the main outcome measure. The probabilistic
sensitivity analysis relied on randomly sampled values
from probability distributions (rather than from a
range deﬁned by upper and lower bounds) to quantify
the total impact of uncertainty on the model out-
comes. In this analysis all model parameters (event
rates and costs listed in Tables 1–3) were varied by the
most probable range and tested for their impact on
CLYG.
Results
Mortality and NNS
The MSP reduced the 10-year mortality rate by 0.2%
(baseline age 70 years) to 0.7% (40 years) more than
OS. With regard to the 10-year mortality rate, the
NNS was 10,000 in MSP compared with OS at the
baseline age of 40 years and 2439 at the baseline age
of 70 years (Table 4). In a population of 100,000
Table 3 Cost of screening, diagnostic measurement, treatment, and range of variability used for the sensitivity analysis
Model parameter Baseline ($) Range ($)* Source
Cost per screening (two-view) including quality 
assessment program
120 104–198 [27,41]
Cost per screening in opportunistic 
screening program (assumption)
160 144–176 [42]†
Cost of complementary examinations for positive
screening result‡
607 546–668 [42]
Cost of initial breast cancer treatment 24,095 21,689–26,505 [43,44]
Cost of recurrent breast cancer treatment 24,095 21,689–26,505 [43,44]
Annual follow-up cost after treated breast cancer
(assumption 10% of breast cancer treatment)
2,410 2,169–2,651 [43]
*Applied range in one-way sensitivity analysis and probabilistic sensitivity analysis.
†Personal communication, Dr. de Landtsheer, 2005.
‡Weighted cost of complementary examinations, including echography and biopsy.
Table 4 Ten-year all-cause mortality and the number needed to screen (NNS) under the baseline assumption of a participation rate
of 70% in MSP and 20% in OS, respectively
Baseline age
(year)
All-cause mortality over 
10 years (%) NNS 
over 10 years to prevent
one death*
Number of extra deaths 
prevented with MSP over OS
per 100,000 women over 
10 years†MSP OS
40 1.448 1.458 10,000 10
50 3.875 3.899 4,167 24
60 9.719 9.754 2,857 35
70 23.782 23.823 2,439 41
*100/(% all-cause mortality OS − % all-cause mortality MSP).
†(% all-cause mortality OS − % all-cause mortality MSP)/100 × 100,000.
MSP, mammography screening program; OS, opportunistic screening.
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women, 10 (40 years) to 41 extra deaths (70 years)
were prevented with MSP over OS.
Costs and Life Expectancy
The total discounted life-time cost (discount rate: 3%)
related to breast cancer, and screening for a 40-year-
old woman amounted in the MSP to $4366 (OS:
$2802) and decreased with age to $2412 (OS: $1446)
at the age of 70 years (Table 5). The discounted incre-
mental life expectancy (discount rates: cost 3%, life
expectancy 1.5%) amounted to 0.022 life-years gained
in favor of MSP when starting screening at age
40 years (0.008 years when starting screening at age
70 years). An alternative scenario, applying a discount
rate of 0%, amounted to a gain in life expectancy of
0.035 with the baseline age of 40 years (0.01 years at
the age of 70 years) (Table 6).
Cost-Effectiveness
Discounted (costs 3%, life expectancy 1.5%) ICER
comparing MSP with OS ranged from $73,018 per
life-year gained (LYG) when screening starts at the
age of 40 years, to $118,193 per LYG (baseline age
70 years) (Table 5). Considering no discount rate in
life expectancy reduced the ICER to $44,005 per LYG
(age 40 years) and $94,353 per LYG (age 70 years),
respectively (Table 6).
Sensitivity and Scenario Analyses
Sensitivity analyses were performed to test the robust-
ness of the outcomes by varying all input parameters
one at a time.
By decreasing order of importance, the most inﬂu-
ential factors for the CLYG-based economic outcome
were breast cancer mortality, the incidence of breast
cancer, the cost of initial tumor treatment, the cost of
biopsy, the cost of MSP, and the sensitivity of MSP
(Fig. 2). The speciﬁcity of OS, the annual recurrence
rate of breast cancer, the annual follow-up cost of
tumor treatment, the expected reduction of breast can-
cer mortality, and the cost of OS showed a marginal
inﬂuence on the CE outcome.
Figure 3 shows that a lower speciﬁcity and/or sen-
sitivity of MSP reduces the economic beneﬁt per LYG
from $75,602 (speciﬁcity 96.5%, sensitivity 70%) to
$507,000 (speciﬁcity 50%, sensitivity 50%).
The result of the probabilistic sensitivity analysis,
which is based on a random assignment of all input
parameter distributions as listed in Tables 1–3, repre-
sents the range and uncertainty of the possible out-
come (Fig. 4). The distribution of ICER ranged from
$45,000 per LYG to $135,000 per LYG with the high-
est probability of occurrence by about $75,000 per
LYG (based on a woman aged 50 years).
An additional analysis indicated that the economic
impact of MSP is also a function of the participation
rates, both in MSP and in OS, in so far as a higher
participation rate in MSP—for a given participation
rate  in  OS—reduced  the  economic  beneﬁt,  whereas
a rise in OS participation improved the efﬁciency
(Fig. 5).
Discussion
This economic modeling analysis of breast cancer
screening combined long-term results from rand-
omized trials with those available from Swiss regional
screening programs to compare the cost-effectiveness
Table 5 Results when MSP is performed in 70% of the population compared with OS in 20% of the population (discount rates: cost
3.0%, life expectancy 1.5%)
Baseline age at start of
screening (year)
Total life time 
cost ($) Incremental life
time cost ($)
Life expectancy
(year) Incremental life 
expectancy (years)
CLYG ($/LYG)
MSP OS MSP OS MSP vs. OS
40 4366 2802 1564 30.674 30.652 0.022 73,018
50 4149 2676 1473 25.322 25.302 0.02 75,602
60 3356 2103 1253 19.663 19.649 0.014 90,635
70 2412 1446 966 13.924 13.916 0.008 118,193
MSP, mammography screening program; OS, opportunistic screening.
Table 6 Results when MSP is performed in 70% of the population compared with OS in 20% of the population (discount rates: cost
3.0%, life expectancy undiscounted)
Baseline age
at start of 
screening
(year)
Total life time
cost ($)
Incremental 
lifetime cost ($)
Life expectancy (year)
Incremental 
life expectancy (year)
CLYG ($/LYG)
MSP OS MSP OS MSP vs. OS
40 4366 2802 1564 41.697 41.662 0.035 44,005
50 4149 2676 1473 32.444 32.415 0.029 50,898
60 3356 2103 1253 23.790 23.771 0.019 66,720
70 2412 1446 966 15.956 15.946 0.01 94,353
CLYG, costs per life-year gained; MSP, mammography screening program; OSP, opportunistic screening.
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of MSP and OS within the liberal Swiss health-care set-
ting. In this particular context, where signiﬁcant health
expenditures arise, the results indicate that MSP is
cost-effective compared with OS. Interestingly, inci-
dence and mortality from breast cancer were the main
inﬂuential factors of the economic outcome, whereas
cost and performances of mammography screening
played a less prominent role.
Figure 2 Ranking of the input parameters in a
univariate sensitivity analysis inﬂuencing the
cost per life-year gained. The age at the start of
the mammography screening program (MSP)
was not considered because of the predominant
effect on life expectancy. The parameters with
the highest impact on the cost per life-year
gained are the annual breast cancer mortality,
the incidence of breast cancer, the cost of initial
tumor treatment, the cost of biopsy, the cost of
MSP, and the sensitivity of MSP.
Sensitivity MSP: range 65 to 
86%
Cost MSP: range +/- 10%
Cost Biopsy: range +/- 10%
Cost initial tumor treatment: 
range +/- 10%
Incidence of breast cancer: 
range +/- 10%
Breast cancer mortality: 
range +/- 10%
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Figure 3 Inﬂuence of test sensitivity and
speciﬁcity on the discounted cost-effectiveness
ratio ($/LYG).  = MSP baseline value of sensi-
tivity (70%) and speciﬁcity (96.5%). LYG, life-
year gained; MSP, mammography screening
program; OS, opportunistic screening.
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Although the association between mammography
screening and breast cancer mortality is complex, sev-
eral studies have shown that early detection can sig-
niﬁcantly reduce breast cancer mortality [10,16]. Most
studies, however, have compared a “screening” versus
a “no screening” scenario. In several countries, includ-
ing Switzerland, mammography screening is delivered
either through an organized public health program
(MSP) or on an individual (private) basis (OS). Because
both screening methods are likely to yield favorable
health beneﬁts to the population, a comparison in rel-
ative terms of both strategies is most relevant for pub-
lic health decision-makers in these countries.
Methods to compare the efﬁcacy of a new health
technology with a given strategy, i.e., screening
method, present the results either as relative risk dif-
ferences or, more appropriately, the overall clinical
beneﬁt, expressed as the number needed to screen
(NNS) to avoid one complication, or as the number of
extra deaths prevented [48,49]. The NNS in the cur-
rent analysis of mammography screening was compa-
rable with ﬁgures found in analogous mammography
screening analyses [10] and in other secondary pre-
vention techniques, e.g., hemoccult testing (NNS to
prevent one colon cancer death: 1300 individuals for
5 years [48]) or osteoporosis screening (NNS to pre-
vent one hip fracture in women aged 50–54 years:
7446 women for 5 years [50]). A recent Australian
study predicted an approximately ﬁve to eight times
greater number of prevented deaths using mammo-
graphy screening than was revealed in the analysis
presented here [49]. This deviation can be mainly
attributed to the proportion of screened and non-
screened women (i.e., 100% and 0% vs. 70% and
30%, respectively) and to a higher reduction of breast
cancer mortality due to screening (i.e., 23–37% vs.
15%, respectively). This ﬁnding shows that the effec-
tiveness of a screening program strongly depends on
the existing health-care system (i.e., well-established
OS).
The number of symptom-free individuals necessary
to detect one case highlights the importance of the reli-
ability of the screening method. Although MSP is not
discussed without criticism, current evidence empha-
sizes that this strategy yields a clear medical beneﬁt for
the female population [10].
Translating these ﬁndings into monetary units
reveals that the additional life-time costs of MSP over
OS are related to the higher life expectancy and the
tumor treatment costs rather than to the cost of screen-
ing itself.
The results are presented in terms of incremental
CLYG values because this is a widely accepted method
in health economic evaluations, which can assist with
the decision-making process. The upper willingness-to-
pay threshold was ﬁxed at a value of $50,000, which
represents “good value for money” for a lifesaving
intervention, according to the international literature
and health economic guidelines [47,51]. The dis-
counted cost-effectiveness ratios of an exhaustive MSP
relative to OS have been found to be on the upper
acceptable threshold value [52].
This result is partly supported by other studies,
especially in analyses performed in older age groups,
which have shown a cost-effectiveness ratio (ICER)
ranging from $34,000 to $88,000 per LYG [53,54].
Other available cost-effectiveness analyses in MSP
present a more favorable ICER within a range from
$3400 to $12,000 per LYG [55–57]. There are several
aspects inﬂuencing the outcome of a cost-effectiveness
analysis, e.g., the decreasing breast cancer mortality
over time and a well-established OS in Switzerland, as
well as the baseline health-care perspective, which is
fundamental in the assessment of different study
outcomes.
The average age in the observed Swiss female pop-
ulation (range 50–95 years) is about 65 years. Apply-
ing this age distribution, one can expect a weighted
and discounted ICER of about $104,000 per LYG
(undiscounted $80,500 per LYG).
Figure 5 Impact of MSP and OS participation
rate on cost-effectiveness ratio. MS, mammog-
raphy screening program; OS, opportunistic
screening.
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Because of the following two conservative assump-
tions in this analysis, there is a trend to overestimate
the cost and underestimate the clinical beneﬁt:
1. considering the competing risk, i.e., evaluating the
screening beneﬁt as a reduction in all-cause mor-
tality rather than breast cancer mortality alone;
and
2. postponing the beneﬁt of MSP and OS in lowering
breast cancer mortality to the subsequent years
whereas the cost of treatment was allocated to the
year of detection.
Our extensive sensitivity analysis of all variables in
the model conﬁrms that both breast cancer incidence
and mortality play a major role in the health economic
outcome, whereas the cost and the performance (sen-
sitivity, speciﬁcity) of screening have a minor impact
on the efﬁciency. From an economic perspective, the
small effect of the screening cost points out the limited
inﬂuence that different regional health-care systems in
Switzerland, which regulate the public copayments of
MSP, have on the cost-effectiveness of mammography
screening.
The model validation performed by the authors (see
Appendix) provides some statistical conﬁdence about
the adequacy of the disease model. Some limitations,
however, are inherent to any modeling approach:
1. A model can only consider the most relevant
aspects of a disease. The resulting picture is less
complex  than  the  reality  but  adequate  enough
to provide the answers to questions asked (e.g.,
reduction of the sensitivity due to hormone
replacement therapy not considered).
2. The applied transition probabilities may vary over
time.  Whether  this  shift  is  illustrated  correctly
in the disease model remains open. Marked ﬂuc-
tuations of breast cancer mortality have been
observed in the last decade, but to what extent
these downward trends are related to screening
activity is difﬁcult to assess [25].
3. Scarce clinical and economic data available for
Switzerland resulted in the inclusion of interna-
tional data, particularly for OS, which leads to
questions regarding the transfer of evidence
between different health-care systems.
4. A nationwide screening program has to take into
account all levels of medical care. It can well be
that relevant differences between different medical
institutions, such as doctors’ ofﬁces and outpa-
tient clinics, exist. This could not be taken into
account for this modeling study (e.g., regional dif-
ferences in the health-care system of Switzerland).
5. A further limitation in this analysis are the missing
health-related quality of life (HRQL) outcomes.
For a comprehensive, population-based consider-
ation of HRQL, health-related utilities are needed
for different circumstances (e.g., false positive
screening result, true negative screening result).
Unfortunately, these kind of HRQL data are
incomplete, and including them would have likely
created a bias in our result.
The development of new technologies (e.g., digital
mammography) could improve various aspects of
breast cancer screening. Whether a new method also
fulﬁll economical claims will decisively depend on the
quality improvement and the prevailing epidemiologi-
cal conditions.
Conclusion
Based on the present decision analysis with its under-
lying assumptions, mammography screening has been
shown to be effective in terms of reducing mortality
and to be worthwhile from an economic perspective.
These ﬁndings are supported by analyses in other
countries. Because these results are derived from a
modeling study, future attention should be paid to the
results of ongoing structured MSP in Switzerland and
the model should be adapted as new evidence arises.
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Appendix
Model Validation
The current mammography model underwent a com-
prehensive validation process. The intention was to
compare the model outcomes with published epidemi-
ological data.
In the ﬁrst step, the difference between the calcu-
lated and the predicted remaining age-speciﬁc life
expectancy was assessed (Table A), using the published
age distribution of women in Switzerland: The maxi-
mum absolute deviation of the calculated remaining
life-years amounts to −0.8 years (−1.9%) in the age
group of 40-year-old women. The deviation between
the calculated and the predicted remaining life-years is
a result of the assessment method in the underlying
data sources: The annual mortality rates used in the
model are based on the 1999 statistics [36,37]. The
model’s predicted remaining life expectancy is derived
from the annual increase in the further life expectancy
and represents therefore a continuous changing
parameter.
In the next step, the difference between the expected
and calculated number of breast cancer cases was
assessed (Table B): The main absolute deviation
between the observed and calculated number of breast
cancer cases per year was −9 cases (−0.9%) in the age
group of 45 to 54 years. The explanation for this devi-
ation can be found in the regression formula, which
was derived from the raw data.
The comparison of expected and calculated
number of annual breast cancer deaths revealed a
main absolute deviation of −15 death cases (−5.6%)
in the age group of 65 to 74 years (Table C): The
most important reason for this deviation is deﬁned in
the method of data collection. To complete the age-
speciﬁc annual breast cancer incidence, data from
different sources were used to perform a regression
analysis.
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Table A Comparison of predicted and model-based remaining
life expectancy for different baseline ages
Table B Comparison of observed and model-based annual
number of breast cancer cases in different age ranges
Age at baseline (year) 
40 50 60 70
Remaining life time
Predicted [36] 42.5 33.0 24.0 15.6
Calculated by the model 41.7 32.4 23.8 15.9
Difference: years (%) −0.8
(−1.9)
−0.6
(−1.8)
−0.2
(−0.8)
+0.3
(−1.9)
Chi-square test of goodness-of-ﬁt: P = 1.00.
Age range (year) 
45–54 55–64 65–74
Annual breast cancer cases
Observed [22] 1074 1258 1023
Calculated by the model 1065 1251 1029
Difference: cases (%) −9 
(−0.9)
−6
(−0.5)
+6
(−0.6)
Chi-square test of goodness-of-ﬁt: P = 0.97.
Table C Comparison of observed and model-based annual
number of breast cancer deaths in different age ranges
Age range (year) 
45–54 55–64 65–74
Annual breast cancer mortality
Observed [37] 159 225 267
Calculated by the model 157 225 252
Difference: cases (%) −2
(−1.3)
0
(0)
−15
(−5.6)
Chi-square test of goodness-of-ﬁt: P = 0.90.
